News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
271,552 Results
Type
Article (7702)
Company Profile (59)
Press Release (263791)
Multimedia
Podcasts (6)
Webinars (6)
Section
Business (95432)
Career Advice (537)
Deals (17597)
Drug Delivery (17)
Drug Development (24300)
Employer Resources (41)
FDA (4396)
Job Trends (5059)
News (141800)
Policy (9224)
Tag
Academia (462)
Accelerated approval (2)
Adcomms (3)
Allergies (16)
Alliances (18639)
ALS (31)
Alzheimer's disease (357)
Antibody-drug conjugate (ADC) (36)
Approvals (4427)
Artificial intelligence (74)
Autoimmune disease (10)
Automation (5)
Bankruptcy (112)
Best Places to Work (3694)
BIOSECURE Act (2)
Biosimilars (30)
Biotechnology (55)
Bladder cancer (18)
Brain cancer (12)
Breast cancer (100)
Cancer (775)
Cardiovascular disease (36)
Career advice (454)
Career pathing (4)
CAR-T (61)
CDC (2)
Cell therapy (174)
Cervical cancer (4)
Clinical research (20349)
Collaboration (349)
Company closure (1)
Compensation (260)
Complete response letters (3)
COVID-19 (586)
CRISPR (21)
C-suite (182)
Cystic fibrosis (23)
Data (895)
Denatured (5)
Depression (19)
Diabetes (67)
Diagnostics (2594)
Digital health (5)
Diversity (1)
Diversity, equity & inclusion (14)
Drug discovery (43)
Drug pricing (16)
Drug shortages (2)
Duchenne muscular dystrophy (32)
Earnings (45263)
Editorial (5)
Employer branding (7)
Employer resources (41)
Events (45205)
Executive appointments (453)
FDA (4853)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (3)
Funding (348)
Gene editing (39)
Generative AI (2)
Gene therapy (78)
GLP-1 (170)
Government (632)
Guidances (98)
Healthcare (6051)
Huntington's disease (7)
IgA nephropathy (15)
Immunology and inflammation (42)
Immuno-oncology (3)
Indications (11)
Infectious disease (614)
Inflammatory bowel disease (36)
Inflation Reduction Act (7)
Influenza (9)
Intellectual property (28)
Interviews (64)
IPO (8931)
IRA (8)
Job creations (1456)
Job search strategy (415)
Kidney cancer (12)
Labor market (11)
Layoffs (140)
Leadership (6)
Legal (2835)
Liver cancer (24)
Lung cancer (83)
Lymphoma (45)
Machine learning (1)
Management (15)
Manufacturing (99)
MASH (37)
Medical device (4523)
Medtech (4525)
Mergers & acquisitions (9043)
Metabolic disorders (189)
Multiple sclerosis (23)
NASH (6)
Neurodegenerative disease (30)
Neuropsychiatric disorders (6)
Neuroscience (560)
NextGen: Class of 2025 (2031)
Non-profit (910)
Now hiring (10)
Obesity (81)
Opinion (46)
Ovarian cancer (32)
Pain (31)
Pancreatic cancer (34)
Parkinson's disease (43)
Partnered (9)
Patents (60)
Patient recruitment (46)
Peanut (6)
People (29511)
Pharmaceutical (13)
Pharmacy benefit managers (2)
Phase I (6378)
Phase II (9081)
Phase III (6822)
Pipeline (868)
Policy (23)
Postmarket research (681)
Preclinical (2570)
Press Release (67)
Prostate cancer (45)
Psychedelics (7)
Radiopharmaceuticals (129)
Rare diseases (115)
Real estate (2303)
Recruiting (14)
Regulatory (6346)
Reports (21)
Research institute (461)
Resumes & cover letters (77)
Rett syndrome (8)
RNA editing (4)
Schizophrenia (44)
Series A (60)
Series B (38)
Service/supplier (4)
Sickle cell disease (9)
Special edition (4)
Spinal muscular atrophy (33)
Sponsored (6)
Startups (1474)
State (1)
Stomach cancer (3)
Supply chain (17)
Tariffs (5)
The Weekly (1)
Vaccines (101)
Venture capital (13)
Weight loss (36)
Women's health (4)
Worklife (1)
Date
Last 7 days (147)
Last 30 days (638)
Last 365 days (11985)
2025 (6405)
2024 (13875)
2023 (16360)
2022 (22599)
2021 (24146)
2020 (21629)
2019 (15628)
2018 (12017)
2017 (12113)
2016 (11134)
2015 (14322)
2014 (11297)
2013 (9167)
2012 (10051)
2011 (10335)
2010 (10047)
Location
Africa (229)
Alabama (18)
Alaska (2)
Arizona (83)
Arkansas (1)
Asia (13550)
Australia (1881)
California (3138)
Canada (1338)
China (140)
Colorado (127)
Connecticut (119)
Delaware (52)
Europe (28801)
Florida (410)
Georgia (53)
Hawaii (1)
Idaho (27)
Illinois (143)
India (8)
Indiana (127)
Iowa (7)
Japan (116)
Kansas (36)
Kentucky (15)
Louisiana (6)
Maine (43)
Maryland (284)
Massachusetts (2228)
Michigan (127)
Minnesota (179)
Mississippi (2)
Missouri (27)
Montana (16)
Nebraska (15)
Nevada (36)
New Hampshire (25)
New Jersey (921)
New Mexico (8)
New York (679)
North Carolina (480)
North Dakota (4)
Northern California (1408)
Ohio (95)
Oklahoma (9)
Oregon (8)
Pennsylvania (508)
Puerto Rico (2)
Rhode Island (15)
South America (335)
South Carolina (11)
Southern California (1214)
Tennessee (55)
Texas (417)
United States (10665)
Utah (75)
Virginia (65)
Washington D.C. (16)
Washington State (249)
West Virginia (3)
Wisconsin (45)
271,552 Results for "lexaria bioscience corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs.”
January 11, 2024
·
3 min read
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Lexaria Bioscience Corp. which will evaluate various DehydraTECH-GLP-1 formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more.
June 18, 2024
·
6 min read
Pharm Country
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Even Better?”.
November 1, 2023
·
3 min read
Pharm Country
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 60+ brands within the Dynamic Brand Portfolio @ IBN a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
January 9, 2024
·
3 min read
Business
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
Lexaria Bioscience Corp. announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately.
March 14, 2024
·
4 min read
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces it has hired a contract research organization to perform the Company’s human pilot study #3, which will evaluate a dual action GLP-1 + GIP.
May 23, 2024
·
5 min read
Pharm Country
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
October 31, 2023
·
3 min read
Press Releases
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
December 17, 2024
·
5 min read
Business
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
Lexaria Bioscience Corp. announces it has hired a contract research organization to perform the Company’s second DehydraTECH-powered glucagon-like peptide 1 human pilot study #2 (the “Study”).
March 7, 2024
·
5 min read
Drug Development
Lexaria’s Submits Investigational New Drug Application
Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the “Company” or “Lexaria”) announces that, on January 29, it submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its planned U.S. phase 1b hypertension clinical trial HYPER-H23-1 of DehydraTECH-CBD.
January 30, 2024
·
5 min read
1 of 27,156
Next
